Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan

Kozo Morimoto, Kiyohiko Izumi, Manabu Ato, Naoki Hasegawa, Satoshi Mitarai

Research output: Contribution to journalArticle

Abstract

Introduction: The details of the practice of treating nontuberculous mycobacterial pulmonary disease (NTMPD) have not been studied in Japan. Methods: We studied a random sample of 2% (184) of the 9,200 patients with incident NTM-PD in 2010 who received standard three-drug therapy for at least some of their treatment between 2010 and 2014. Results: The median duration of the standard treatment period was 248 days (IQR 56–540 days). Although 59% of the patients were treated with standard therapy for more than 6 months, only 41% were treated for 12 months. Fifty-three patients (29%) initiated treatment with substandard regimen, and 18 (34%) of those patients received treatment regimens that can lead to the development of macrolide resistance (MR)(CLR monotherapy or CLR + RIF). Furthermore, initially, 184 receiving the standard treatment, 49 patients (27%) eventually deviated from it, and 31 patients (63%) received regimens increasing the risk of developing MR. The sporadic administration of macrolide monotherapy was observed before and after the administration of the standard treatment for 50 patients (27.7%) and 41 patients (27.2%), respectively. Conclusions: Approximately 60% of the treated patients did not continue the standard regimen for more than 12 months and 42% were at risk for developing MR before and after receiving the standard treatment. It is important to educate physicians and patients about the correct and safe management of NTMPD.

Original languageEnglish
Pages (from-to)67-69
Number of pages3
JournalRespiratory Medicine
Volume158
DOIs
Publication statusPublished - 2019 Oct 1

Fingerprint

Japan
Lung
Macrolides
Therapeutics
Lung Diseases
Physicians
Drug Therapy

Keywords

  • Clarithromycin resistant
  • Guideline
  • Insurance claim
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan. / Morimoto, Kozo; Izumi, Kiyohiko; Ato, Manabu; Hasegawa, Naoki; Mitarai, Satoshi.

In: Respiratory Medicine, Vol. 158, 01.10.2019, p. 67-69.

Research output: Contribution to journalArticle

Morimoto, Kozo ; Izumi, Kiyohiko ; Ato, Manabu ; Hasegawa, Naoki ; Mitarai, Satoshi. / Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan. In: Respiratory Medicine. 2019 ; Vol. 158. pp. 67-69.
@article{41722d93406e473599cb9e17cc210c90,
title = "Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan",
abstract = "Introduction: The details of the practice of treating nontuberculous mycobacterial pulmonary disease (NTMPD) have not been studied in Japan. Methods: We studied a random sample of 2{\%} (184) of the 9,200 patients with incident NTM-PD in 2010 who received standard three-drug therapy for at least some of their treatment between 2010 and 2014. Results: The median duration of the standard treatment period was 248 days (IQR 56–540 days). Although 59{\%} of the patients were treated with standard therapy for more than 6 months, only 41{\%} were treated for 12 months. Fifty-three patients (29{\%}) initiated treatment with substandard regimen, and 18 (34{\%}) of those patients received treatment regimens that can lead to the development of macrolide resistance (MR)(CLR monotherapy or CLR + RIF). Furthermore, initially, 184 receiving the standard treatment, 49 patients (27{\%}) eventually deviated from it, and 31 patients (63{\%}) received regimens increasing the risk of developing MR. The sporadic administration of macrolide monotherapy was observed before and after the administration of the standard treatment for 50 patients (27.7{\%}) and 41 patients (27.2{\%}), respectively. Conclusions: Approximately 60{\%} of the treated patients did not continue the standard regimen for more than 12 months and 42{\%} were at risk for developing MR before and after receiving the standard treatment. It is important to educate physicians and patients about the correct and safe management of NTMPD.",
keywords = "Clarithromycin resistant, Guideline, Insurance claim, Treatment",
author = "Kozo Morimoto and Kiyohiko Izumi and Manabu Ato and Naoki Hasegawa and Satoshi Mitarai",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.rmed.2019.10.002",
language = "English",
volume = "158",
pages = "67--69",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan

AU - Morimoto, Kozo

AU - Izumi, Kiyohiko

AU - Ato, Manabu

AU - Hasegawa, Naoki

AU - Mitarai, Satoshi

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Introduction: The details of the practice of treating nontuberculous mycobacterial pulmonary disease (NTMPD) have not been studied in Japan. Methods: We studied a random sample of 2% (184) of the 9,200 patients with incident NTM-PD in 2010 who received standard three-drug therapy for at least some of their treatment between 2010 and 2014. Results: The median duration of the standard treatment period was 248 days (IQR 56–540 days). Although 59% of the patients were treated with standard therapy for more than 6 months, only 41% were treated for 12 months. Fifty-three patients (29%) initiated treatment with substandard regimen, and 18 (34%) of those patients received treatment regimens that can lead to the development of macrolide resistance (MR)(CLR monotherapy or CLR + RIF). Furthermore, initially, 184 receiving the standard treatment, 49 patients (27%) eventually deviated from it, and 31 patients (63%) received regimens increasing the risk of developing MR. The sporadic administration of macrolide monotherapy was observed before and after the administration of the standard treatment for 50 patients (27.7%) and 41 patients (27.2%), respectively. Conclusions: Approximately 60% of the treated patients did not continue the standard regimen for more than 12 months and 42% were at risk for developing MR before and after receiving the standard treatment. It is important to educate physicians and patients about the correct and safe management of NTMPD.

AB - Introduction: The details of the practice of treating nontuberculous mycobacterial pulmonary disease (NTMPD) have not been studied in Japan. Methods: We studied a random sample of 2% (184) of the 9,200 patients with incident NTM-PD in 2010 who received standard three-drug therapy for at least some of their treatment between 2010 and 2014. Results: The median duration of the standard treatment period was 248 days (IQR 56–540 days). Although 59% of the patients were treated with standard therapy for more than 6 months, only 41% were treated for 12 months. Fifty-three patients (29%) initiated treatment with substandard regimen, and 18 (34%) of those patients received treatment regimens that can lead to the development of macrolide resistance (MR)(CLR monotherapy or CLR + RIF). Furthermore, initially, 184 receiving the standard treatment, 49 patients (27%) eventually deviated from it, and 31 patients (63%) received regimens increasing the risk of developing MR. The sporadic administration of macrolide monotherapy was observed before and after the administration of the standard treatment for 50 patients (27.7%) and 41 patients (27.2%), respectively. Conclusions: Approximately 60% of the treated patients did not continue the standard regimen for more than 12 months and 42% were at risk for developing MR before and after receiving the standard treatment. It is important to educate physicians and patients about the correct and safe management of NTMPD.

KW - Clarithromycin resistant

KW - Guideline

KW - Insurance claim

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85072919384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072919384&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2019.10.002

DO - 10.1016/j.rmed.2019.10.002

M3 - Article

C2 - 31605924

AN - SCOPUS:85072919384

VL - 158

SP - 67

EP - 69

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -